Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

DoH confirms "commuter surgery" locations:

This article was originally published in Clinica

Executive Summary

The DoH has confirmed the location of the seven so-called "commuter surgeries" that are due to open this year at some of the UK's busiest railway stations. The surgeries, modelled on the growing network of NHS Walk-in Centres designed to complement general practice and A&E hospital care, will be based at London's Liverpool Street, Canary Wharf, Kings Cross and Victoria stations; Manchester's Piccadilly and Newcastle's Central stations; and in Leeds (New Station Street). Around £25m ($47m) will be invested in these over the next three years. Each of the centres will treat over 30,000 cases per year, according to DoH estimates, backed by the results of a MORI survey of commuters, published last week. There are 61 NHS Walk-in Centres in operation, attending an average of 115 patients per day; a further 21 centres are currently under development.

You may also be interested in...



Will MDR Delays Create Roadblocks For Companion Diagnostics Regulation?

Companion diagnostics are needed increasingly by pharma companies to justify the safety and effectiveness of their products. With specific first-time EU regulation of these products within sight – and urgently needed is there a risk of delays to these products being able to demonstrate compliance?

India Rare Disease Policy Proposes Crowdfunding But Patients Feel Let Down

Draft policy moots crowdfunding for high-cost rare diseases alongside financial support for those "amenable to one-time treatment" but falls way short of some patient groups' expectations.

India’s Hilleman Plans ‘Affordable’ Vaccine Against Group B Strep

India’s Hilleman Laboratories says it’s aiming to develop an affordable vaccine that will target pregnant women in low- and middle-income countries to prevent Group B Streptococcus, a potentially fatal infection passed to babies during childbirth.

Topics

UsernamePublicRestriction

Register

MT053999

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel